Side-by-side · Research reference

EpitalonvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/37 cited

BPhase 1Reviewed10/36 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Epitalon

GHRP-6

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

—

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

GHRP-6

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

100–200 mcg per injectionBowers 1990

Frequency

Once daily during a cycle

1–3× per day

Lower / starter dose

2.5 mg / day

50 mcg per dose

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Phase 1 + clinical practiceBowers 1990

Duration

10–20 day cycles, 1–2× per year

8–12 weeks on / 4 off

Reconstitution

Bacteriostatic water

Timing

Pre-sleep preferred (pineal alignment)

Pre-meal preferred for appetite support

Half-life

Hours (estimated)

~15 minMalagón 1999

04Side Effects & Safety

Parameter

Epitalon

GHRP-6

Injection site reaction

Mild irritation

Mild

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

Contraindicated in active malignancy

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

Antibody formation

Not reported

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Epitalon

·Family history of cancer

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

Epitalon

GHRP-6

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Injection site

SQ — abdomen preferred. Rotate sites.

SQ — abdomen. Rotate sites.

3. Timing

Pre-sleep preferred to align with pineal axis.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.